<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="X-UA-Compatible" content="ie=edge" />
    <title>Quiz Complete</title>
    <link rel="stylesheet" href="app.css" />
  </head>
  <body>
    <div class="container">
      <div id="end" class="flex-center flex-column">
	   <h1>Your score:</h1>
        <h4 id="finalScore"></h4></br>
		<h1>Possible Points: 25 </h1>
        <a class="btn" href="index.html">Table of Contents</a>
		<h1> For all questions and answers, please scroll down</h1></br>
      </div>
    </div>
	<h1> Chapter 13: Hematological Pathology Answers </h1>
	<p>	question: "Q1. Which of the following is not classified as a microcytic anemia?",</br>
    choice1: "Iron deficiency",</br>
    choice2: "Thalassemia",</br>
    choice3: "Anemia of chronic disease",</br>
    choice4: "Aplastic anemia",</br>
	choice5: "Sideroblastic anemia",</br>
    answer: 4</br>
</br>
    question: "Q2. Which of the following anemias will not show an increased reticulocyte count?",</br>
    choice1: "Fanconi anemia",</br>
    choice2: "Hemolytic anemia",</br>
    choice3: "Hemorrhagic anemia",</br>
    choice4: "Partially treated folic acid deficiency",</br>
	choice5: "Glucose-6-phophate dehydrogenase (G6PD) deficiency",</br>
    answer: 1</br>
</br>
    question: "Q3. Which of the following does not demonstrate Burr cells in a blood smear?",</br>
    choice1: "Acute renal failure",</br>
    choice2: "Bleeding ulcer",</br>
    choice3: "Myelofibrosis",</br>
    choice4: "Gastric carcinoma",</br>
	choice5: "Pyruvate kinase deficiency",</br>
    answer: 3</br>
</br>
    question: "Q4. Spherocytes may appear with all of the following except?",</br>
    choice1: "Hemoglobin C disease",</br>
    choice2: "Transfusion",</br>
    choice3: "Autoimmune hemolytic anemia",</br>
    choice4: "Burns",</br>
	choice5: "ABO incompatibility",</br>
    answer: 1</br>
</br>
    question: "Q5. Which condition is not usually associated with the presence of schistocytes?",</br>
    choice1: "Thrombotic throbocytopenic purpura",</br>
    choice2: "Hemolytic uremic syndrome",</br>
    choice3: "Severe burns",</br>
    choice4: "Disseminated intravascular coagulation",</br>
	choice5: "Hereditary elliptocytosis",</br>
    answer: 5</br>
</br>
    question: "Q6. Rouleaux formation is seen in all the following except?",</br>
    choice1: "Paraproteinemia",</br>
    choice2: "Multiple myeloma",</br>
    choice3: "Hereditary spherocytosis",</br>
    choice4: "Diabetes mellitus",</br>
	choice5: "Acute and chronic inflammation",</br>
    answer: 3</br>
</br>
    question: "Q7. Which condition does not show target cells in a peripheral blood smear?",</br>
    choice1: "Thalassemia",</br>
    choice2: "Iron deficiency anemia",</br>
    choice3: "Liver disease",</br>
    choice4: "Megaloblastic anemia",</br>
	choice5: "Hemoglobin C disease",</br>
    answer: 4</br>
</br>
    question: "Q8. Ovalocytes are seen in all the following conditions except?",</br>
    choice1: "Thalassemia",</br>
    choice2: "Iron deficiency anemia",</br>
    choice3: "folate deficiency",</br>
    choice4: "Chronic liver disease",</br>
	choice5: "Sideroblastic anemia",</br>
    answer: 5</br>
</br>
    question: "Q9. Which of the following is not associated with stomatocytes in a peripheral blood smear?",</br>
    choice1: "Myelofibrosis",</br>
    choice2: "Immune hemolytic anemia",</br>
    choice3: "Rh null syndrome",</br>
    choice4: "Chronic liver disease",</br>
	choice5: "Erythrocytotoxic agents",</br>
    answer: 1</br>
</br>
    question: "Q10. Which of the following conditions is not usually associated with teardrop cells?",</br>
    choice1: "Splenectomy",</br>
    choice2: "Aplastic anemia",</br>
    choice3: "Myelofibrosis",</br>
    choice4: "Thalassemia",</br>
	choice5: "Metastatic bone marrow",</br>
    answer: 2</br>
</br>
    question: "Q11. Acanthocytes are typically seen in all of the following conditions except?",</br>
    choice1: "Abetalipoproteinemia",</br>
    choice2: "Chronic alcoholism",</br>
    choice3: "Sickle cell anemia",</br>
    choice4: "Severe liver disease",</br>
	choice5: "Splenectomy",</br>
    answer: 3</br>
</br>
    question: "Q12. Which of the following conditions may not show t(9;22)?",</br>
    choice1: "Acute myeloid leukemia",</br>
    choice2: "Chronic myelogenous leukemia",</br>
    choice3: "Acute B-lymphoblastic leukemia/lymphoma",</br>
    choice4: "Acute T-lymphoblastic leukemia/lymphoma",</br>
	choice5: "All of the above",</br>
    answer: 4</br>
</br>
    question: "Q13. Which of the following statements about chronic myelogenous leukemia (CML) is not correct?",</br>
    choice1: "BCR-ABL1 fusion is the most important factor in pathogenesis in CML",</br>
    choice2: "Tyrosine kinase inhibitors are the main treatment modality in treatment of CML",</br>
    choice3: "Increased blast percentage >10% but less than 20% is the only diagnostic criteria for progression of CML into accelerated phase",</br>
    choice4: "CML cases with normal cytogenetic studies may show BCR-ABL1 fusion gene by reverse transcription polymerase chain reaction (RT-PCR)",</br>
	choice5: "Transformed CML cases are associated with alteed TP53, MYC or AML1/EVI1 genes",</br>
    answer: 3</br>
</br>
    question: "Q14. Which of the following statements about polycythemia vera (PV) is not correct?",</br>
    choice1: "The annual incidence of PV in western countries is higher than in Japan and East Asia",</br>
    choice2: "Most PV patients (>95%) demonstrate subnormal erythropoietin (EPO), endogenous erythroid colony (EEC) or JAK2 matuations",</br>
    choice3: "Most PV cases demonstrate sufficient morphological features, even in the early prepolycythemic stage",</br>
    choice4: "Most PV cases (>95%) show no evidence of stainable iron in bone marrow aspirate and biopsy",</br>
	choice5: "Later myelofibrotic stages of PV are defined by progressive erythropoiesis and decreased megakaryocytic proliferation",</br>
    answer: 5</br>
</br>
    question: "Q15. Which of the following statements is not applicable to primary myelofibrosis (PMF)?",</br>
    choice1: "The prefibrotic stage of PMF is characterized by hypercellular marrow with atyoical megakaryocytic proliferation",</br>
    choice2: "The fibrotic stage of PMF is associated with the presence of frequent teardrop red cells in peripheral blood",</br>
    choice3: "The prefibrotic stage of PMF is associated with the presence of frequent teardrop red cells in peripheral blood",</br>
    choice4: "Marked increase in bone marrow reticulin fibrosis and intravascular hematoipoeisis are characteristic morphological findings seen in PMF",</br>
	choice5: "Atypical megakaryocytes with cloud-like nuclei and extramedullary hematopoieisis are common features of PMF",</br>
    answer: 3</br>
</br>
    question: "Q16. Which of the following statements is not applicable to essential thrombocythemia (ET)?",</br>
    choice1: "Persistent marked thrombocytosis >450 E9/L is a diagnostic feature of ET, especially when it is supported by the presence of JAK2 mutation",</br>
    choice2: "Some ET cases with marked thrombocytosis are associated with chromosome 3 abnormalities",</br>
    choice3: "Bone marrow biopsy may be helpful to exclude other myeloid neoplasms presenting with thrombocytosis - e.g. myelodysplastic syndrome (MDS) with del </br>(5q) or refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T)",</br>
    choice4: "Proliferation of giant megakaryocytic forms displaying staghorn lobulated nuclei is a characteristic feature of ET",</br>
	choice5: "ET cases demonstrate JAK2 V617F mutation (40-50%) and/or CALR mutation (20%) or MPL mutation (5%)",</br>
    answer: 2</br>
</br>
    question: "Q17. Which of the following statements is no applicable to chronic myelomonocytic leukemia (CMML)?",</br>
    choice1: "Presence of persistent monocytosis (> 1.0 E9/L) with unknown cause for at least 3 months is the first precondition for the diagnosis of CMML",</br>
    choice2: "CMML cases may demonstrate mild to moderate bone marrow dysplasia",</br>
    choice3: "CMML cases with eosinophilia associated with t(5;12) do not require further molecular or genetic testing for subclassification",</br>
    choice4: "Extramedullary involvement of splenic red pulp, skin, hepatic sinusoids and lymph nodes may be seen with CMML",</br>
	choice5: "Nodular proliferation of plasmacytoid dendritic cells (plasmacytoid monocytes) is amorphological feature seen in CMML cases",</br>
    answer: 3</br>
</br>
    question: "Q18. Which of the following statements about myelodysplastic syndrome (MDS) is not correct?",</br>
    choice1: "Dysplastic megakaryocytes and dyserythropoiesis may be seen with exposure to chemo agents, viral infections, toxins and congenital disorders",</br>
    choice2: "Wth the avialability of SF3B1 mutation, ringed sideroblasts are not required for the diagnosis of refractory anemia with ringed sideroblasts (RARS)",</br>
    choice3: "The clinical significance of presence of Auer rods in MDS cases with less than 5% blasts is unknown",</br>
    choice4: "Pelger-Huet neutrophils may be seen in MDS as well as nonneoplastic conditions",</br>
	choice5: "Approximately 10% of MDS cases may demonstrate hypoplastic marrow or bonne marrow fibrosis",</br>
    answer: 2</br>
</br>
    question: "Q19. Which of the following statements about acute myeloid leukemia (AML) with recurrent genetic abnormalities is not correct?",</br>
    choice1: "All myeloid neoplasms with t(8;21)(q22;q22), in(16)(p13.1;q22) and t(15;17(q22;q12) regardless of blast count are classified as AML",</br>
    choice2: "Blasts in AML with t(8;21)(q22;q22) usually demonstrate abundant granular cytoplasm with prominent perinuclear halo and increased eosinophilic precursors",</br>
    choice3: "All myeloid neoplasms with t(9;11)(p23;q34), inv(3)(q21;q26.2) and t(3;3(q21;q26.2), regardless of blast count, are also diagnosed with AML",</br>
    choice4: "AML cases inv(16)(p13.1;q22) usually demonstrate myelomonocytic features with variable number of eosinophilic precursors with large eosinophilic granules",</br>
	choice5: "Acute promyelocytic leukemia (APL) cases with t(15;17) PML-RARA are sensitive to treatment with all trans-retinoic acid (ATRA) and expression of CD56 is associated with less favourable prognosis",</br>
    answer: 3</br>
</br>
    question: "Q20. Which of the following statements is not applicable to variants of AML?",</br>
    choice1: "Most AML cases with myelodysplasia-related changes have a history of previous cytotoxic therapy",</br>
    choice2: "On the 2016 WHO revised classification, most of the previously diagnosed acute erythroleukemia cases (erythroid/myeloid subtype) will be categorized as MDS-RAEB2",</br>
    choice3: "Therapy related myeloid neoplasms, including t-AML/t-MDS or t-AML/t-MDS/t-MPN, account for 10-20% of AML cases and are usually correlated to a </br>previous treatment with alkylating agents/radiation therapy",</br>
    choice4: "Case of AML with minimal differntiation presenting with medium size agranular blasts may require immunophenotypic studies to be distinguished </br>from acute lymphoblastic leukemia (ALL) or megaloblastic leukemia",</br>
	choice5: "AML with maturation cases account for 10% of AML cases and frequently display Auer rods. Promyelocytes, myelocytes and neutrophils account for </br>at least 10% of bone marrow cells",</br>
    answer: 1</br>
</br>
    question: "Q21. Which immunophenotypic marker is not usually present on immature stem cells or early progenitor/precursor lymphoid blasts?",</br>
    choice1: "TdT",</br>
    choice2: "CD34",</br>
    choice3: "CD1a",</br>
    choice4: "CD10",</br>
	choice5: "CD68",</br>
    answer: 5</br>
</br>
    question: "Q22. B-lymphoblastic leukemia/lymphoma is the most common type of acute leukemia in children. What clinical and cytogenetic/molecular factors adversely </br>affect the prognosis for children with this disease?",</br>
    choice1: "Age less than 2 years and less than 10 years",</br>
    choice2: "WBC count at presentation greater than 100 000",</br>
    choice3: "MLL gene aberrations",</br>
    choice4: "Presence of t(9;22)",</br>
	choice5: "All of the above",</br>
    answer: 5</br>
</br>
    question: "Q23. Whcih of the following statements is not applicable to B-lymphoblastic leukemia/lymphoma (B-ALL)?",</br>
    choice1: "Many treatment protocols consider 25% blast count in bone marrow as a cutoff for defining this neoplasm as acute lymphoblastic leukemia",</br>
    choice2: "B-ALL is most common in children and 75% of cases occur in children under 6 years of age",</br>
    choice3: "The most common form of extramedullary involvement is mediastinal mass",</br>
    choice4: "Patients with B-lymphoblastic lymphoma without leukemia are usually asymptomatic and most have a limited stage disease",</br>
	choice5: "B-ALL has a good prognosis and greater than 95% of children with ALL show complete remission",</br>
    answer: 3</br>
</br>
    question: "Q24. Which of the following statements about T-lymphoblastic leukemia/lymphoma (T-ALL) is not correct?",</br>
    choice1: "T-ALL cases account for 15% of childhood ALL and are more common in adolescent males",</br>
    choice2: "T-ALL cases are usually present with high leukocyte counts; however, the diagnosis should be avoided when blasts are less than 20%. Compared to</br> B-ALL trilineage hematopoiesis is relatively spared",</br>
    choice3: "T-ALL cases with hyperdiploid chromosomes are commonly seen among older children and are associated with a very favourable prognosis",</br>
    choice4: "T-ALL cases are usually TdT positive and express cytoplasmic CD3 with frequent coexpression of CD4 and CD8 (thymocyte T cell immunophenotype)",</br>
	choice5: "T-ALL in childhood is a high risk disease and no favourable subtypes with recurrent genetic abnormalities have been recognized for this entity",</br>
    answer: 3</br>
</br>
    question: "Q25. Which of the following immunophenotypic features are not seen with neoplastic plasma cells?",</br>
    choice1: "Expression of CD138, CD38, EMA, MUM1",</br>
    choice2: "Expression of cyclin D1/D3",</br>
    choice3: "Monotypic immunoglobulin light chain restriction",</br>
    choice4: "Aberrant expression of CD56 and CD117",</br>
	choice5: "Absence of CD45/CD20/CD43",</br>
    answer: 5</br>
    
    <script src="c13hemeend.js"></script>
  </body>
</html>
